We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

73 hedge funds and large institutions have $103M invested in Sierra Oncology, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 29 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

867% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 3

367% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 6

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

43% more funds holding

Funds holding: 51 → 73 (+22)

11% less capital invested

Capital invested by funds: $115M → $103M (-$12.9M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $21K

Holders
73
Holders Change
+22
Holders Change %
+43.14%
% of All Funds
1.67%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
28
Increased
29
Reduced
3
Closed
6
Calls
–
Puts
$21K
Net Calls
-$21K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$8.82M
2
PM
Prosight Management
Texas
+$7.2M
3
NLVP
New Leaf Venture Partners
New York
+$6.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.96M
5
A
Abingworth
United Kingdom
+$4.09M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.83M
2
AC
AWH Capital
Texas
-$1.37M
3
EP
Eversept Partners
New York
-$250K
4
Two Sigma Investments
Two Sigma Investments
New York
-$245K
5
JG
Jefferies Group
New York
-$224K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$459K +$628K +5,541 +92,350%
GT
27
Greenleaf Trust
Michigan
$447K +$23.4K +206 +4%
BCM
28
Bridgeway Capital Management
Texas
$444K +$142K +1,250 +30%
SAM
29
Sectoral Asset Management
Quebec, Canada
$417K – – –
AC
30
AWH Capital
Texas
$414K -$1.37M -12,125 -71%
CH
31
CVI Holdings
Delaware
$392K +$537K +4,738 New
Fidelity Investments
32
Fidelity Investments
Massachusetts
$354K – – –
MIM
33
Monashee Investment Management
Massachusetts
$300K +$411K +3,625 New
BFM
34
Boothbay Fund Management
New York
$287K +$393K +3,467 New
KAM
35
Kazazian Asset Management
Florida
$256K +$351K +3,095 New
Acadian Asset Management
36
Acadian Asset Management
Massachusetts
$254K +$256K +2,261 +279%
TI
37
Telemetry Investments
New York
$207K +$283K +2,500 New
SI
38
Sofinnova Investments
California
$203K +$278K +2,453 New
Goldman Sachs
39
Goldman Sachs
New York
$184K +$251K +2,218 New
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$170K +$162K +1,432 +232%
DS
41
DRW Securities
Illinois
$166K +$113K +1,000 +100%
DCM
42
DAFNA Capital Management
California
$166K +$227K +1,999 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$155K – – –
William Blair & Company
44
William Blair & Company
Illinois
$115K +$27.7K +244 +21%
UBS Group
45
UBS Group
Switzerland
$111K +$153K +1,345 New
Two Sigma Investments
46
Two Sigma Investments
New York
$92K -$245K -2,161 -66%
PAM
47
Panagora Asset Management
Massachusetts
$91K – – –
CC
48
Caxton Corporation
New Jersey
$78K +$107K +940 New
ASN
49
Advisory Services Network
Georgia
$77K – – –
PNC Financial Services Group
50
PNC Financial Services Group
Pennsylvania
$76K +$37.1K +327 +56%
1
2
3 4

SRRA Hedge Fund Activity: Q1 2018 in Review

73 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2018, worth a combined $103M — down 11% from $115M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new SRRA positions and 6 closed out — a net gain of 22 holders — while 29 added to existing stakes and 3 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $8.82M. The largest seller was OrbiMed, cutting an estimated $2.83M.

  • 73 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2018, up from 51 in Q4 2017.
  • Funds reported $103M of Sierra Oncology, Inc. Common Stock stock for Q1 2018, down 11% quarter-over-quarter.
  • 28 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2018 and 6 closed out, a net change of +22 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2018 was Great Point Partners, an estimated $8.82M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q1 2018 was OrbiMed, an estimated $2.83M sold.

Based on aggregated 13F filings for Q1 2018.